These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML. Lalayanni C; Gavriilaki E; Athanasiadou A; Iskas M; Papathanasiou M; Marvaki A; Mpesikli S; Papaioannou G; Mallouri D; Batsis I; Papalexandri A; Sakellari I; Anagnostopoulos A Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):e233-e240. PubMed ID: 34756570 [TBL] [Abstract][Full Text] [Related]
6. Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission. Michelis FV; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Lipton JH; Loach D; Seftel MD; Uhm J; Alam N; Lambie A; McGillis L; Messner HA Bone Marrow Transplant; 2015 Jul; 50(7):907-13. PubMed ID: 25822226 [TBL] [Abstract][Full Text] [Related]
7. Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. Chen X; Othus M; Wood BL; Walter RB; Becker PS; Percival ME; Abkowitz JL; Appelbaum FR; Estey EH Leuk Lymphoma; 2021 May; 62(5):1226-1233. PubMed ID: 33345655 [TBL] [Abstract][Full Text] [Related]
8. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Schmaelter AK; Labopin M; Socié G; Itälä-Remes M; Blaise D; Yakoub-Agha I; Forcade E; Cornelissen J; Ganser A; Beelen D; Labussière-Wallet H; Passweg J; Savani BN; Schmid C; Nagler A; Mohty M Blood Cancer J; 2020 Mar; 10(3):26. PubMed ID: 32127519 [TBL] [Abstract][Full Text] [Related]
9. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Gardin C; Pautas C; Fournier E; Itzykson R; Lemasle E; Bourhis JH; Adès L; Marolleau JP; Malfuson JV; Gastaud L; Raffoux E; Lambert J; Braun T; Thomas X; Chantepie S; Cluzeau T; de Botton S; Berthon C; Boissel N; Duployez N; Terré C; Peffault de Latour R; Michallet M; Celli-Lebras K; Preudhomme C; Dombret H Blood Adv; 2020 May; 4(9):1942-1949. PubMed ID: 32380535 [TBL] [Abstract][Full Text] [Related]
10. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. De Witte T; Muus P; De Pauw B; Haanen C Cancer; 1990 Sep; 66(5):831-7. PubMed ID: 2386911 [TBL] [Abstract][Full Text] [Related]
11. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Larson RA Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252 [TBL] [Abstract][Full Text] [Related]
12. Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt. Sedeta E; Jemal A; Nisotel L; Sung H Cancer; 2024 Jun; 130(11):1952-1963. PubMed ID: 38244208 [TBL] [Abstract][Full Text] [Related]
13. Defining Acute Myeloid Leukemia Ontogeny in Older Patients. Melody M; Kuykendall A; Sallman D; Al Ali N; Zhang L; Talati C; Padron E; Sweet K; Extermann M; List A; Lancet J; Komrokji R Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):312-315. PubMed ID: 32139296 [TBL] [Abstract][Full Text] [Related]
14. Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia. Higgins A; Shah MV Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32640569 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Milosevic JD; Puda A; Malcovati L; Berg T; Hofbauer M; Stukalov A; Klampfl T; Harutyunyan AS; Gisslinger H; Gisslinger B; Burjanivova T; Rumi E; Pietra D; Elena C; Vannucchi AM; Doubek M; Dvorakova D; Robesova B; Wieser R; Koller E; Suvajdzic N; Tomin D; Tosic N; Colinge J; Racil Z; Steurer M; Pavlovic S; Cazzola M; Kralovics R Am J Hematol; 2012 Nov; 87(11):1010-6. PubMed ID: 22887079 [TBL] [Abstract][Full Text] [Related]
16. Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease. Collinge E; Loron S; Larcher MV; Elhamri M; Heiblig M; Deloire A; Ducastelle S; Labussière H; Barraco F; Wattel E; Salles G; Paubelle E; Thomas X Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):e211-e218. PubMed ID: 29572159 [TBL] [Abstract][Full Text] [Related]
17. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. Rogers HJ; Wang X; Xie Y; Davis AR; Thakral B; Wang SA; Borthakur G; Cantu MD; Margolskee EM; Philip JKS; Sukhanova M; Bagg A; Bueso-Ramos CE; Orazi A; Arber DA; Hsi ED; Hasserjian RP Am J Hematol; 2020 Jul; 95(7):799-808. PubMed ID: 32249963 [TBL] [Abstract][Full Text] [Related]
18. Characterization and prognostic features of secondary acute myeloid leukemia in survivors of multiple myeloma. Jia J; Chen W Am J Cancer Res; 2023; 13(10):4803-4810. PubMed ID: 37970345 [TBL] [Abstract][Full Text] [Related]
19. Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features. Yabe M; Tang G; Garcia-Manero G; Loghavi S; Lu X; Miranda RN; Medeiros LJ; Kantarjian HM; Bueso-Ramos CE; Khoury JD Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S85-90. PubMed ID: 26297286 [TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy. Dan C; Chi J; Wang L Ann Med; 2015 May; 47(3):209-17. PubMed ID: 25861829 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]